IMFINZI Specific-Clinical Experience Investigation in patients with NSCLC after definitive chemoradiation therapy

Trial Identifier: D4194C00003
Sponsor: AstraZeneca
NCTID:: NCT03643484
Start Date: October 2018
Primary Completion Date: June 2021
Study Completion Date: June 2021
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Japan Kumamoto, Japan, D4194C00003
Japan Miyazaki, Japan, D4194C00003
Japan Tottori, Japan, D4194C00003
Japan Toyama, Japan, D4194C00003
Japan Yamagata, Japan, D4194C00003
Japan Yamanashi, Japan, D4194C00003